Yahoo Web Search

Search results

1. • 

     What is hypochlorous acid? The ingredient hyped as an acne hack, explained by dermatologists

     CBS News· 5 days ago

     Hypochlorous acid is the latest skin care ingredient making waves on social media, with users...

2. • 

     Study Finds Link Between Hip Fracture and Dementia Later On

     Medscape· 5 days ago

     Older adults who fracture their hip are more likely to experience dementia than their peers who...

3. • Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...

     Benzinga· 2 days ago

     Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly

4. • Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides...

     WKRN Nashville· 7 days ago

     Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing ...

5. • 

     What’s Your Story? Contest Finalists

     The Scientist· 6 days ago

     Earlier this year, The Scientist, in partnership with Thermo Fisher Scientific, launched What’s Your Story?, a science writing competition that...

6. • AbbVie (NYSE:ABBV) Now Covered by Cantor Fitzgerald

     ETF DAILY NEWS· 3 days ago

     Cantor Fitzgerald assumed coverage on shares of AbbVie (NYSE:ABBV – Get Free Report) in a research note issued to investors on Friday, MarketBeat.com reports. Cantor Fitzgerald’s price objective ...

7. • Apogee Therapeutics, Inc. (NASDAQ:APGE) Sees Large Growth in Short Interest

     ETF DAILY NEWS· 5 days ago

     Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) saw a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,840,000 shares, ...

8. • Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

     Benzinga· 2 days ago

     NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive

9. • 

     Morning Brew: MicroStrategy Soars on MSCI Inclusion, Walmart Bea

     Guru Focus· 6 days ago

     Today's stock market is showing positive signs with slight gains across major indices. Here's a...

10. • 

      J&J hooks Proteologix for $850M cash, reeling in a roster of early bispecifics

      FierceBiotech· 6 days ago

      Johnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of...